• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Allergy Therapeutics - Articles and news items

Aloxi needle

First patient recruited in Pollinex Quattro Birch dose ranging study in Germany and Austria

Industry news / 1 September 2015 / Nick Jackson

As a precursor to the Phase III trial, this Phase IIb study will select the optimum dose, and is being conducted in Germany under the Therapy Allergens Ordinance (Therapieallergene-Verordnung)…